Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CFI-402411 |
| Trade Name | |
| Synonyms | CFI 402411|CFI402411 |
| Drug Descriptions |
CFI-402411 inhibits MAP4K1 (HPK1), potentially leading to enhanced T-lymphocyte activation and antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| DrugClasses | MAP4K1 Inhibitor 8 |
| CAS Registry Number | NA |
| NCIT ID | C176963 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CFI-402411 | CFI-402411 | 0 | 1 |
| CFI-402411 + Pembrolizumab | CFI-402411 Pembrolizumab | 0 | 1 |